Journalists

Media & Press relations

Our latest press releases

November 05, 2025

Oxford Nanopore and bioMérieux launch AmPORE-TB, a Research Use Only sequencing-based solution to rapidly characterize drug resistant-tuberculosis

Oxford Nanopore Technologies and bioMérieux have announced the launch of AmPORE-TB, a Research Use Only (RUO) solution for the rapid characterization of mutations associated with antimicrobial resistance in Mycobacterium tuberculosis complex, using Oxford Nanopore sequencing technology.

Discover more

Swipe for more

November 04, 2025

Third-Quarter 2025 Business Review

bioMérieux, a world leader in the field of in vitro diagnostics, today releases its business review for the nine months ended September 30, 2025. Consolidated sales amounted to €2,992 million for the first nine months of 2025 versus €2,871 million for the prior-year period, representing a growth of +4.2% as reported.

Read more
September 04, 2025

First-Half 2025 Financial Results

Consolidated sales amounted to €2,044 million in the first-half of 2025 from €1,902 million in the prior year period, a +9.4% like-for-like growth.

Read more
August 18, 2025

bioMérieux receives U.S. FDA 510(k) clearance and CLIA-waiver for Anterior Nasal Swab specimens, an additional sample type for use with the BIOFIRE® SPOTFIRE® R/ST Panel Mini

bioMérieux today announces that its BIOFIRE® SPOTFIRE® R/ST Panel Mini has received U.S. FDA 510(k) clearance and CLIA waiver for the addition of Anterior Nasal Swab as a validated specimen type for this panel.

Read more